These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1010 related articles for article (PubMed ID: 22184384)
1. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. Lee J; Lim DH; Kim S; Park SH; Park JO; Park YS; Lim HY; Choi MG; Sohn TS; Noh JH; Bae JM; Ahn YC; Sohn I; Jung SH; Park CK; Kim KM; Kang WK J Clin Oncol; 2012 Jan; 30(3):268-73. PubMed ID: 22184384 [TBL] [Abstract][Full Text] [Related]
2. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. Park SH; Sohn TS; Lee J; Lim DH; Hong ME; Kim KM; Sohn I; Jung SH; Choi MG; Lee JH; Bae JM; Kim S; Kim ST; Park JO; Park YS; Lim HY; Kang WK J Clin Oncol; 2015 Oct; 33(28):3130-6. PubMed ID: 25559811 [TBL] [Abstract][Full Text] [Related]
3. Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer. Ustaalioglu BBO; Bilici A; Tilki M; Surmelioglu A; Erkol B; Figen M; Uyar S J Cancer Res Ther; 2018 Sep; 14(Supplement):S736-S741. PubMed ID: 30249896 [TBL] [Abstract][Full Text] [Related]
4. Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial. Yu JI; Lim DH; Ahn YC; Lee J; Kang WK; Park SH; Park JO; Park YS; Lim HY; Kim ST; Kim S; Sohn TS; Choi MG; Bae JM; Nam H Radiother Oncol; 2015 Oct; 117(1):171-7. PubMed ID: 26299196 [TBL] [Abstract][Full Text] [Related]
5. Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy. Jansen EP; Boot H; Dubbelman R; Bartelink H; Cats A; Verheij M Br J Cancer; 2007 Sep; 97(6):712-6. PubMed ID: 17848909 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ; Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693 [TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321 [TBL] [Abstract][Full Text] [Related]
8. A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II). Tsuburaya A; Morita S; Kodera Y; Kobayashi M; Shitara K; Yamaguchi K; Yoshikawa T; Yoshida K; Yoshino S; Sakamoto J BMC Cancer; 2012 Jul; 12():307. PubMed ID: 22824079 [TBL] [Abstract][Full Text] [Related]
9. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. Kim ST; Kang JH; Lee J; Park SH; Park JO; Park YS; Lim HY; Hwang IG; Lee SC; Park KW; Lee HR; Kang WK Eur J Cancer; 2014 Nov; 50(16):2822-30. PubMed ID: 25218337 [TBL] [Abstract][Full Text] [Related]
10. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. Lee SS; Kim SB; Park SI; Kim YH; Ryu JS; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH Jpn J Clin Oncol; 2007 Nov; 37(11):829-35. PubMed ID: 17951334 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection. Kwon HC; Kim MC; Kim KH; Jang JS; Oh SY; Kim SH; Kwon KA; Lee S; Lee HS; Kim HJ Asia Pac J Clin Oncol; 2010 Dec; 6(4):278-85. PubMed ID: 21114777 [TBL] [Abstract][Full Text] [Related]
12. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial Park SH; Lim DH; Sohn TS; Lee J; Zang DY; Kim ST; Kang JH; Oh SY; Hwang IG; Ji JH; Shin DB; Yu JI; Kim KM; An JY; Choi MG; Lee JH; Kim S; Hong JY; Park JO; Park YS; Lim HY; Bae JM; Kang WK; Ann Oncol; 2021 Mar; 32(3):368-374. PubMed ID: 33278599 [TBL] [Abstract][Full Text] [Related]
13. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Kang YK; Kang WK; Shin DB; Chen J; Xiong J; Wang J; Lichinitser M; Guan Z; Khasanov R; Zheng L; Philco-Salas M; Suarez T; Santamaria J; Forster G; McCloud PI Ann Oncol; 2009 Apr; 20(4):666-73. PubMed ID: 19153121 [TBL] [Abstract][Full Text] [Related]
14. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial. Nishikawa K; Tsuburaya A; Yoshikawa T; Takahashi M; Tanabe K; Yamaguchi K; Yoshino S; Namikawa T; Aoyama T; Rino Y; Kawada J; Tsuji A; Taira K; Kimura Y; Kodera Y; Hirashima Y; Yabusaki H; Hirabayashi N; Fujitani K; Miyashita Y; Morita S; Sakamoto J Gastric Cancer; 2018 Sep; 21(5):811-818. PubMed ID: 29488122 [TBL] [Abstract][Full Text] [Related]
15. [A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy]. Mihara K; Yamashiro N; Nishiya S; Kemmochi T; Ito Y; Egawa T; Nagashima A Gan To Kagaku Ryoho; 2014 Nov; 41(12):2358-60. PubMed ID: 25731522 [TBL] [Abstract][Full Text] [Related]
16. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. Dikken JL; Jansen EP; Cats A; Bakker B; Hartgrink HH; Kranenbarg EM; Boot H; Putter H; Peeters KC; van de Velde CJ; Verheij M J Clin Oncol; 2010 May; 28(14):2430-6. PubMed ID: 20368551 [TBL] [Abstract][Full Text] [Related]
17. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer. Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507 [TBL] [Abstract][Full Text] [Related]
18. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). Dikken JL; van Sandick JW; Maurits Swellengrebel HA; Lind PA; Putter H; Jansen EP; Boot H; van Grieken NC; van de Velde CJ; Verheij M; Cats A BMC Cancer; 2011 Aug; 11():329. PubMed ID: 21810227 [TBL] [Abstract][Full Text] [Related]
19. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II). Nishikawa K; Tsuburaya A; Yoshikawa T; Kobayashi M; Kawada J; Fukushima R; Matsui T; Tanabe K; Yamaguchi K; Yoshino S; Takahashi M; Hirabayashi N; Sato S; Nemoto H; Rino Y; Nakajima J; Aoyama T; Miyagi Y; Oriuchi N; Yamaguchi K; Miyashita Y; Morita S; Sakamoto J Eur J Cancer; 2018 Sep; 101():220-228. PubMed ID: 30096702 [TBL] [Abstract][Full Text] [Related]
20. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M; Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]